Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan:145:102855.
doi: 10.1016/j.critrevonc.2019.102855. Epub 2019 Dec 20.

Triple negative breast cancer: A thorough review of biomarkers

Jesse Lopes da Silva  1 , Natalia Cristina Cardoso Nunes  2 , Patricia Izetti  2 , Guilherme Gomes de Mesquita  2 , Andreia Cristina de Melo  2
Affiliations
Review

Triple negative breast cancer: A thorough review of biomarkers

Jesse Lopes da Silva et al. Crit Rev Oncol Hematol. 2020 Jan.

Abstract

Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The tumorigenesis is not likely to be driven by hormonal or HER2 pathway. In comparison to other types of breast cancer, TNBC stands out for its aggressive behavior, more prone to early recurrence. Historically, TNBC has been considered a disease with poor response to molecular target therapy, requiring better validation of biomarkers. Recent issues related to tumor heterogeneity have been widely discussed suggesting the subdivision of TNBC into different molecular subtypes. Through a complete research on the main published trials databases and platforms of ongoing clinical studies, the current manuscript was carried out in order to present a critical view of the role of immunohistochemical and molecular biomarkers for the prognosis and response prediction of TNBC to traditional therapy and new molecular target agents.

Keywords: BRCA mutation; Biomarkers; Molecular target therapy; PD-L1; Triple-negative breast cancer; Tumor-infiltrating lymphocytes.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest No potential conflicts of interest were disclosed by the authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources